Thermo Fisher Scientific has put forward a DNA-based test it says can offer much more precise identification of blood and its potential compatibility—going much further than the traditional positive and negative blood types of A, B, AB and O.

Having stacked all its chips on the idiopathic pulmonary fibrosis (IPF) treatment buloxibutid, Vicore Pharma’s bet may be paying off.

After picking up $100 million in venture capital cash earlier this month, Karius is adding another feather to its cap with a breakthrough designation from the FDA.

Eli Lilly finds itself in a familiar position: snapping at the heels of Novo Nordisk. The Indianapolis-based drugmaker kept itself in the slipstream of its regular foe Thursday with positive top-line data from a pair of phase 3 studies of its once-weekly insulin candidate.

The FDA has approved two diagnostic devices that allow women to collect vaginal samples themselves for cervical cancer screening—a major step toward catching more early and potentially preventable cases without requiring an invasive gynecological exam.

Vaxxinity, which filed to delist from the Nasdaq last month, is choosing radical transparency about the “abusive relationship” that has defined the immunotherapy medicine company’s three-year stint as a public company.

In January 2023, Verily Life Sciences began to pull back from the many different areas of the healthcare sector in which it once played to better tailor its bets on becoming a more profitable company.

Flatiron Health’s technology for connecting electronic health records and electronic data captures in clinical trials will be integrated into the Association of Cancer Care Center’s (ACCC’s) network of community cancer centers, according to a May 13 press release. Financial terms of the deal were not disclosed.

The legal risk of excluding pregnant and lactating people from clinical trials outweighs the liability of including them, a Congress-commissioned report from the National Academies of Science, Engineering and Medicine (NASEM) has found.

The FDA has elevated a pair of separate recalls from Route 92 Medical and Boston Scientific for issues stemming from their cardiovascular catheters for treating strokes and diagnosing conditions in the heart.